Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
4.950
-0.120 (-2.37%)
At close: Dec 20, 2024, 4:00 PM
4.990
+0.040 (0.81%)
After-hours: Dec 20, 2024, 5:47 PM EST
Company Description
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States.
The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis.
It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019.
Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Sagimet Biosciences Inc.
| Country | United States |
| Founded | 2006 |
| IPO Date | Jul 14, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | David Happel |
Contact Details
Address: 155 Bovet Road, Suite 303 San Mateo, California 94402 United States | |
| Phone | 650 561 8600 |
| Website | sagimet.com |
Stock Details
| Ticker Symbol | SGMT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001400118 |
| CUSIP Number | 786700104 |
| ISIN Number | US7867001049 |
| Employer ID | 20-5991472 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David A. Happel | Chief Executive Officer, President and Director |
| Dr. George W. Kemble Ph.D. | Executive Chairman of the Board |
| Dr. Eduardo Bruno Martins DPhil, M.D., Ph.D. | Chief Medical Officer |
| Urs Greber Ph.D. | Co-Founder |
| Dr. Lucas Pelkmans Ph.D. | Co-Founder |
| Thierry Chauche | Chief Financial Officer and Principal Accounting Officer |
| Elizabeth Rozek Esq., J.D. | General Counsel and Chief Compliance Officer |
| Dr. Marie O'Farrell Ph.D. | Senior Vice President of Research and Development |
| Robert D'Urso | Senior Vice President of New Products |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Aug 26, 2024 | EFFECT | Notice of Effectiveness |
| Aug 19, 2024 | UPLOAD | Filing |
| Aug 16, 2024 | 8-K | Current Report |
| Aug 15, 2024 | S-3 | Registration statement under Securities Act of 1933 |